drugset / Trial / NCT05161806
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
NaSingle-groupOpen-labelTreatment
Summary
This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.
Timeline
- Start
- 2022-03-11
- Primary completion
- 2022-05-04
- Completion
- 2022-05-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SOK583A1 | Protein / enzyme biologic | 2 mg | Intravitreal |